Risks of High Testosterone Levels

Cardiovascular and Hematologic Risks

Erythrocytosis (elevated hematocrit) is a common and potentially serious complication of high testosterone levels, with incidence varying by administration route: 43.8% with intramuscular injections versus 15.4% with transdermal patches 1
The risk of erythrocytosis increases with testosterone dosage - occurring in 2.8% of men receiving 5 mg/day via nonscrotal patches, 11.3% with 50 mg/day gel preparations, and 17.9% with 100 mg/day gel preparations 1
Elevated hematocrit can increase blood viscosity, potentially aggravating vascular disease in coronary, cerebrovascular, or peripheral vascular circulation, particularly in elderly individuals 2
The risk of hemoconcentration is greater in individuals with conditions already associated with increased hematocrit, such as chronic obstructive pulmonary disease 2

While there is no compelling evidence that high testosterone directly causes prostate cancer, it may potentially stimulate growth of occult prostate cancer 3, 4
Benign prostatic hyperplasia (BPH) is a rare but potential risk associated with high testosterone levels 1
Monitoring of PSA levels and digital rectal examination is recommended for men with high testosterone levels to detect any prostate abnormalities early 5

Sleep apnea may be exacerbated by high testosterone levels 1, 6
Skin conditions such as acne can develop or worsen 1
Gynecomastia (breast enlargement in men) can occur due to conversion of excess testosterone to estradiol 1
Testicular atrophy and infertility are common with sustained high testosterone levels 1
Fluid retention may occur 6

Supraphysiologic doses of androgens, particularly oral nonaromatizable androgenic steroids, can lower high-density lipoprotein (HDL) levels 7
However, physiologic testosterone levels generally show neutral effects on lipid profiles, with most studies showing no change or minimal reduction in HDL, often accompanied by reduction in total cholesterol 7, 8
Only very high doses of testosterone (600 mg/week, well into the supraphysiologic range) are associated with significant HDL reduction 8

Regular monitoring of hematocrit or hemoglobin levels is essential to detect erythrocytosis early 1, 5
If erythrocytosis develops, appropriate measures include dosage reduction, withholding testosterone, therapeutic phlebotomy, or blood donation 1
Regular prostate monitoring with PSA testing and digital rectal examination is recommended 5
Assessment for sleep apnea symptoms should be performed regularly 5

The elderly are at particularly high risk for complications from erythrocytosis due to increased likelihood of underlying vascular disease 2
Individuals with pre-existing conditions that increase hematocrit (like COPD) require extra vigilance 2